



Andreas Lohri

Contact

Andreas Lohri

Publications (14)

Moccia A, Rauch D, Vorobiof D, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Raats J, Del Giglio A, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Zucca E. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. *Blood Adv* 2020; 4:5951-5957.

Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhausern R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. *Blood Adv* 2020; 4:3699-3707.

Zucca E, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S, Ghielmini M, Kimby E, Novak U, Lohri A, Ferreri A, Rondeau S, Vanazzi A, Østenstad B, Mey U, Rauch D, Wahlin B, Hitz F, Hernberg M, Johansson A, de Nully Brown P, Hagberg H, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. *Blood* 2019; 134:353-362.

Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet* 2017; 390:2790-2802.

Taverna C, Zucca E, Heijnen I, Rusterholz C, Rondeau S, Biaggi Rudolf C, Lohri A, Vorobiof D, Rauch D, Raats J, Laszlo D, Vanazzi A, Del Giglio A, Cevreska L, Pabst T, Mingrone W, Hitz F, Martinelli G, Ghielmini M. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. *J Clin Oncol* 2015; 34:495-500.

Müller R, Renner C, Gabay C, Cassata G, Lohri A, Hasler P. The advent of biosimilars: challenges and risks. *Swiss Med Wkly* 2014; 144:w13980.

Hitz F, Bargetzi M, Cogliatti S, Lohri A, Taverna C, Renner C, Mey U. Diagnosis and treatment of mantle cell lymphoma. *Swiss Med Wkly* 2013; 143:w13868.

Forrer F, Oechsli-Oberholzer C, Campana B, Herrmann R, Maecke H, Mueller-Brand J, Lohri A. Radioimmunotherapy with ¹⁷⁷Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. *J Nucl Med* 2013; 54:1045-52.

Renner C, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N, Bouabdallah K, Trojan A, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. *Haematologica* 2012; 97:1085-91.

Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. *J Clin Oncol* 2010; 28:4480-4.

Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribi K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). *Onkologie* 2010; 33:222-8.

Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, Moldenhauer G, Maecke H. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. *Eur J Nucl Med Mol Imaging* 2009; 36:1443-52.

Ghielmini M, Vorobiof D, Bargetzi M, Lohri A, Helg C, Kovacsovics T, Stupp R, Zucca E, Hess U, Peccatori F, Martinelli G, Betticher D, Fey M, Waltzer U, Hummerjohann J, Pichert G, Cogliatti S, Schmitz S, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood* 2004; 103:4416-23.

D'Addario G, Ketterer N, Fey M, Cavalli F, Lohri A, Egli F, Stahel R, Maibach R, Torhorst J, Dieterle A, Cerny T. HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study. *Leukemia & lymphoma* 2003; 44:133-8.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch